The third-generation aromatase inhibitors provide novel approaches to the endocrine treatment of breast cancer. These drugs are effectively challenging tamoxifen, the previous gold standard of ...

Aromatase inhibitors are a class of hormonal agents that form part of the therapy for some types of breast cancer. ... androstenedione and testosterone are converted to estrone and estradiol.

Aromatase inhibitors act through pure oestrogen deprivation to achieve an endocrine response in oestrogen receptor (ER)-positive breast cancer. Both experimental and clinical data now confirm that ...

Compared with placebo and baseline measurements, aromatase inhibition increased mean serum testosterone levels by ∼ 50% at 3 months. However, mean androgen levels decreased between months 3 and ...

For patients receiving up-front treatment with tamoxifen, the extension of tamoxifen 2,3 or an aromatase inhibitor to 10 years has been shown to be beneficial in reducing the ongoing risk of ...

Aromatase inhibitors are an effective treatment for postmenopausal women with hormone receptor-positive breast cancer. But they do put patients at a higher risk of musculoskeletal symptoms and ...

The product, T+Ai TM , is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication ...